nach oben

Current HIV/AIDS Reports

Erschienen in:

12.02.2020 | HIV Pathogenesis and Treatment (AL Landay and NS Utay, Section Editors)

Novel Antiretroviral Agents

verfasst von: Mary C. Cambou, Raphael J. Landovitz

Erschienen in: Current HIV/AIDS Reports | Ausgabe 2/2020

Einloggen, um Zugang zu erhalten

Abstract

Purpose of Review

Combination antiretroviral therapy (cART) has had dramatic effects on morbidity and mortality for persons living with HIV (PLWH). Despite significant progress in treatment efficacy, tolerability, and reducing pill burden, new agents are needed to address issues of resistance, drug-drug interactions, end organ disease, and adherence. This review covers novel ART agents recently approved or in development.

Recent Findings

Capsid inhibitors (CAI) demonstrate high potency and potential for extended-duration dosing in pre-clinical trials. While previous maturation inhibitors (MI) were hampered by issues of drug resistance, a recent phase IIa trial for a second-generation MI demonstrated promising antiviral activity. A phase I trial to evaluate a transdermal implant of islatravir, a nucleoside reverse transcriptase translocation inhibitor (NRTTI), maintained concentrations above the target pharmacokinetic threshold at 12 weeks. The attachment inhibitor fostemsavir is available in the USA for compassionate use in multi-drug-resistant (MDR) HIV.

Summary

New antiretroviral agents show promise for both extended-duration dosing and MDR HIV.

Ghosn J, Taiwo B, Seedat S, Autran B, Katlama C. HIV. Lancet. 2018;392(10148):685–97.CrossRef

Fischl MA, Richman DD, Grieco MH, Gottlieb MS, Volberding PA, Laskin OL, et al. The efficacy of azidothymidine (AZT) in the treatment of patients with AIDS and AIDS-related complex. A double-blind, placebo-controlled trial. N Engl J Med. 1987;317(4):185–91.CrossRef

Hammer SM, Squires KE, Hughes MD, Grimes JM, Demeter LM, Currier JS, et al. A controlled trial of two nucleoside analogues plus indinavir in persons with human immunodeficiency virus infection and CD4 cell counts of 200 per cubic millimeter or less. AIDS Clinical Trials Group 320 Study Team. N Engl J Med. 1997;337(11):725–33.CrossRef

Gulick RM, Mellors JW, Havlir D, Eron JJ, Gonzalez C, McMahon D, et al. Treatment with indinavir, zidovudine, and lamivudine in adults with human immunodeficiency virus infection and prior antiretroviral therapy. N Engl J Med. 1997;337(11):734–9.CrossRef

World Health Organization. Updated recommendations on first-line and second-line antiretroviral regimens and post-exposure prophylaxis and recommendations on early infant diagnosis of HIV: interim guidelines: supplement to the 2016 consolidated guidelines on the use of antiretroviral drugs for treating and preventing HIV infection. 2018.

Thenin-Houssier S, Valente ST. HIV-1 capsid inhibitors as antiretroviral agents. Curr HIV Res. 2016;14(3):270–82.CrossRef

Blair WS, Pickford C, Irving SL, Brown DG, Anderson M, Bazin R, et al. HIV capsid is a tractable target for small molecule therapeutic intervention. PLoS Pathog. 2010;6(12):e1001220.CrossRef

Campbell EM, Hope TJ. HIV-1 capsid: the multifaceted key player in HIV-1 infection. Nat Rev Microbiol. 2015;13(8):471–83.CrossRef

Carnes SK, Sheehan JH, Aiken C. Inhibitors of the HIV-1 capsid, a target of opportunity. Curr Opin HIV AIDS. 2018;13(4):359–65.CrossRef

10.

Tse WL, Link JO, Mulato A, Niedziela-Majka A, Rowe W, Somoza JR, Villasenor AG, Yant SR, Zhang JR, Zheng J. Discovery of novel potent HIV capsid inhibitors with long-acting potential. Conference on Retroviruses and Opportunistic Infections. Seattle, Washington; 2017.

11.

Yant SR, Mulato A, Hansen D, Tse WC, Niedziela-Majka A, Zhang JR, et al. A highly potent long-acting small-molecule HIV-1 capsid inhibitor with efficacy in a humanized mouse model. Nat Med. 2019;25(9):1377–84.CrossRef

12.

Perrier M, Bertine M, Le Hingrat Q, Joly V, Visseaux B, Collin G, et al. Prevalence of gag mutations associated with in vitro resistance to capsid inhibitor GS-CA1 in HIV-1 antiretroviral-naive patients. J Antimicrob Chemother. 2017;72(10):2954–5.CrossRef

13.

Zheng J, Yant SR, Ahmadyar S, Chan TY, Chiu A, Cihlar T, Link JO, Lu B, Mwangi JW, Rowe W, Schroeder SD, Stepan GJ, Wang KW, Subramanian R, Tse WC. GS-6207: a novel, potent and selective first-in-class inhibitor of HIV 1 capsid function displays nonclinical pharmacokinetics supporting long acting potential in humans. IDSA Annual Meeting. San Francisco, California; 2018.

14.

Safety, pharmacokinetics, and antiviral activity of GS-6207 administered subcutaneously in HIV-1 infected adults. [Available from: https://ClinicalTrials.gov/show/NCT03739866].

15.

Mascolini M. Sharp drops in HIV load after 10 days of capsid inhibitor monotherapy. International AIDS Society. Mexico City, Mexico; 2019.

16.

Hwang C, Schürmann D, Sobotha C, Boffito M, Sevinsky H, Ray N, et al. Secondgeneration HIV‐1 maturation inhibitor BMS‐955176: antiviral activity and safety with atazanavir +/- ritonavir. International AIDS Society. Vancouver, Canada; 2015.

17.

Smith PF, Ogundele A, Forrest A, Wilton J, Salzwedel K, Doto J, et al. Phase I and II study of the safety, virologic effect, and pharmacokinetics/pharmacodynamics of single-dose 3-o-(3′, 3′-dimethylsuccinyl) betulinic acid (bevirimat) against human immunodeficiency virus infection. Antimicrob Agents Chemother. 2007;51(10):3574–81.CrossRef

18.

McCallister S, Lalezari J, Richmond G, Thompson M, Harrigan R, Martin D, et al. HIV-1 Gag polymorphisms determine treatment response to bevirimat (PA-457). Antivir Ther. 2008;13(Suppl 3):A10.

19.

Van Baelen K, Salzwedel K, Rondelez E, Van Eygen V, De Vos S, Verheyen A, et al. Susceptibility of human immunodeficiency virus type 1 to the maturation inhibitor bevirimat is modulated by baseline polymorphisms in Gag spacer peptide 1. Antimicrob Agents Chemother. 2009;53(5):2185–8.CrossRef

20.

Nowicka-Sans B, Protack T, Lin Z, Li Z, Zhang S, Sun Y, et al. Identification and characterization of BMS-955176, a second-generation HIV-1 maturation inhibitor with improved potency, antiviral spectrum, and Gag polymorphic coverage. Antimicrob Agents Chemother. 2016;60(7):3956–69.CrossRef

21.

Hwang C, Schürmann D, Sobotha C, Boffito M, Sevinsky H, Ray N, et al. Antiviral activity, safety, and exposure–response relationships of GSK3532795, a second-generation human immunodeficiency virus type 1 maturation inhibitor, administered as monotherapy or in combination with atazanavir with or without ritonavir in a phase 2a randomized, dose-ranging, controlled trial (AI468002). Clin Infect Dis. 2017;65(3):442–52.CrossRef

22.

Morales-Ramirez J, Bogner JR, Molina JM, Lombaard J, Dicker IB, Stock DA, et al. Safety, efficacy, and dose response of the maturation inhibitor GSK3532795 (formerly known as BMS-955176) plus tenofovir/emtricitabine once daily in treatment-naive HIV-1-infected adults: week 24 primary analysis from a randomized phase IIb trial. PLoS One. 2018;13(10):e0205368.CrossRef

23.

DeJesus E, Harward S, Jewell RC, Johnson M, Dumont E, Wilches V, Halliday F, Talarico C, Jeffrey J, Gan K, Felizarta FB, Scribner A, Rampogal M, Benson P, Johns BA. A phase IIa study of novel maturation inhibitor GSK2838232 in HIV patients. Conference on Retroviruses and Opportunistic Infections. Seattle, Washington; 2019.

24.

Johnson M, Jewell RC, Peppercorn A, Gould E, Xu J, Lou Y, et al. The safety, tolerability, and pharmacokinetic profile of GSK2838232, a novel 2nd generation HIV maturation inhibitor, as assessed in healthy subjects. Pharmacol Res Perspect. 2018;6(4):e00408.CrossRef

25.

Matthews RP, Schurmann D, Rudd DJ, Levine V, Fox-Bosetti S, Zhang S, et al. Single doses as low as 0.5 mg of the novel NRTTI MK-8591 suppress HIV for at least seven days. Paris: International AIDS Society Conference; 2017.

26.

Grobler J, Fillgrove K, Hazuda D, Huang Q, Lai M, Matthews RP, Rudd DJ, Vargo R. MK-8591 potency and PK provide high inhibitory quotients at low doses QD and QW. Conference on Retroviruses and Opportunistic Infections; Seattle, Washington; 2019.

27.

Grobler J, Friedman E, Barrett S, Wood S, Androm W, Fillgrove K, Lai M, Gindy M, Iwamoto M, Hazuda D. Long-acting oral and parenteral dosing of MK-8591 for HIV treatment or prophylaxis. Conference on Retroviruses and Opportunistic Infections. Boston, Massachusetts; 2016.

28.

Markowitz M, Gettie A, St Bernard L, Mohri H, Grasperge B, Blanchard J, Sun L, Fillgrove K, Hazuda D, Grobler J. Low dose MK-8591 protects rhesus macaques against rectal SHIV infection. Conference on Retroviruses and Opportunistic Infections. Boston, Massachusetts; 2018.

29.

Safety and pharmacokinetics of oral islatravir (MK-8591) once monthly in participants at low risk of human immunodeficiency virus 1 (HIV-1) infection (MK-8591-016). [Available from: https://clinicaltrials.gov/ct2/show/NCT04003103].

30.

Matthews R. First-in-human trial of MK-8591-eluting implants demonstrates concentrations suitable for HIV prophylaxis for at least one year. International AIDS Society Conference. Mexico City, Mexico; 2019.

31.

• Barrett SE, Teller RS, Forster SP, Li L, Mackey MA, Skomski D, et al. Extended-duration MK-8591-eluting implant as a candidate for HIV treatment and prevention. Antimicrob Agents Chemother. 2018;62(10):e01058–18 This study evaluated the pharmacokinetics of islatravir-eluting implants in rhesus macaques.CrossRef

32.

Burkly LC, Olson D, Shapiro R, Winkler G, Rosa JJ, Thomas DW, et al. Inhibition of HIV infection by a novel CD4 domain 2-specific monoclonal antibody. Dissecting the basis for its inhibitory effect on HIV-induced cell fusion. J Immunol. 1992;149(5):1779–87.PubMed

33.

Moore J, Sattentau Q, Klasse P, Burkly L. A monoclonal antibody to CD4 domain 2 blocks soluble CD4-induced conformational changes in the envelope glycoproteins of human immunodeficiency virus type 1 (HIV-1) and HIV-1 infection of CD4+ cells. J Virol. 1992;66(8):4784–93.CrossRef

34.

Boon L, Holland B, Gordon W, Liu P, Shiau F, Shanahan W, et al. Development of anti-CD4 MAb hu5A8 for treatment of HIV-1 infection: preclinical assessment in non-human primates. Toxicology. 2002;172(3):191–203.CrossRef

35.

Pace CS, Fordyce MW, Franco D, Kao C-Y, Seaman MS, Ho DD. Anti-CD4 monoclonal antibody ibalizumab exhibits breadth and potency against HIV-1, with natural resistance mediated by the loss of a V5 glycan in envelope. J Acquir Immune Defic Syndr. 2013;62(1):1–9.CrossRef

36.

Toma J, Weinheimer SP, Stawiski E, Whitcomb JM, Lewis ST, Petropoulos CJ, et al. Loss of asparagine-linked glycosylation sites in variable region 5 of human immunodeficiency virus type 1 envelope is associated with resistance to CD4 antibody ibalizumab. J Virol. 2011;85(8):3872–80.CrossRef

37.

Khanlou H DJ, Fessel J, Schrader S, Towner W, Weinheimer S, Lewis S. Durable efficacy and continued safety of ibalizumab in treatment-experienced patients. IDSA Annual Meeting. Boston, Massachusetts; 2011.

38.

• Emu B, Fessel J, Schrader S, Kumar P, Richmond G, Win S, et al. Phase 3 study of ibalizumab for multidrug-resistant HIV-1. N Engl J Med. 2018;379(7):645–54 This study demonstrated that ibalizumab had significant antiviral activity in adults with MDR HIV-1, prompting FDA approval.CrossRef

39.

Chong H, Yao X, Zhang C, Cai L, Cui S, Wang Y, et al. Biophysical property and broad anti-HIV activity of albuvirtide, a 3-maleimimidopropionic acid-modified peptide fusion inhibitor. PLoS One. 2012;7(3):e32599.CrossRef

40.

Buzon V, Natrajan G, Schibli D, Campelo F, Kozlov MM, Weissenhorn W. Crystal structure of HIV-1 gp41 including both fusion peptide and membrane proximal external regions. PLoS Pathog. 2010;6(5):e1000880.CrossRef

41.

Ding X, Zhang X, Chong H, et al. Enfuvirtide (T20)-Based Lipopeptide Is a Potent HIV-1 Cell Fusion Inhibitor: Implications for Viral Entry and Inhibition. J Virol. 2017;91(18). https://doi.org/10.1128/JVI.00831-17

42.

Zhang H, Jin R, Yao C, Zhang T, Wang M, Xia W, et al. Combination of long-acting HIV fusion inhibitor albuvirtide and LPV/r showed potent efficacy in HIV-1 patients. AIDS Res Ther. 2016;13:8.CrossRef

43.

Xie D. Efficacy and safety of long acting HIV fusion inhibitor albuvirtide in antiretroviral-experienced adults with HIV-1: interim 48-week results from the randomized, controlled, phase 3, non-inferiority TALENT study. HIV Glasgow. Glasgow, UK; 2016.

44.

Albuvirtide. U.S. Department of Health and Human Services. [Available from: https://aidsinfo.nih.gov/drugs/586/albuvirtide/0/patient].

45.

Albuvirtide and 3BNC117 as long-acting maintenance therapy in virologically suppressed subjects (ABL). [Available from: https://clinicaltrials.gov/ct2/show/NCT03719664?cond=albuvirtide&draw=2&rank=2].

46.

Lataillade M, Lalezari J, Aberg J, Molina JM, Kozal M, Cahn P, et al. Week 96 safety and efficacy of the novel HIV-1 attachment inhibitor prodrug fostemsavir in heavily treatment-experienced participants infected with multi-drug-resistant HIV-1 (BRIGHTE Study). International AIDS Society Conference. Mexico City, Mexico; 2019.

47.

ViiV Compassionate Use. 2019. [Available from: https://viiv-cu-portal.idea-point.com/Documents/Status%20of%20drugs%20in%20the%20ViiV%20Compassionate%20Use%20Program.pdf].

48.

Al-Salama ZT. Elsulfavirine: first global approval. Drugs. 2017;77(16):1811–6.CrossRef

49.

Ratanasuwan W, Peerawong W, Koryakova A, Berzins B, Bichko V, Murphy R. Pharmacokinetics of VM-1500 20 mg and 40 mg in healthy and HIV-infected patients. International AIDS Society Conference. Melbourne, Australia; 2014.

50.

Phase Ib study of safety, tolerability and pharmacokinetics of elpida once weekly in healthy volunteers. [Available from: https://clinicaltrials.gov/ct2/show/NCT03730311].

51.

Murphy R, Kravchenko A, Orlova-Morozova E, Nagimova F, Kozirev O, Shimonava T, Deulina M, Vostokova N, Zozulya O, Bichko V. Elsulfavirine as compared to efavirenz in combination with TDF/FTC: 48-week study. Conference on Retroviruses and Opportunistic Infections. Seattle, Washington; 2017.

Titel: Novel Antiretroviral Agents
verfasst von: Mary C. Cambou
Raphael J. Landovitz
Publikationsdatum: 12.02.2020
Verlag: Springer US
Erschienen in: Current HIV/AIDS Reports / Ausgabe 2/2020
Print ISSN: 1548-3568
Elektronische ISSN: 1548-3576
DOI: https://doi.org/10.1007/s11904-020-00486-2

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Neu im Fachgebiet Innere Medizin

23.04.2024 | Ablationstherapie | Nachrichten

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Live-Webinar: Aktuelle Leitlinien bei Herz-Kreislauf-Erkrankungen

Springer Medizin

Novel Antiretroviral Agents

Abstract

Purpose of Review

Recent Findings

Summary

Leitlinien kompakt für die Innere Medizin

Neu im Fachgebiet Innere Medizin

Wie erfolgreich ist eine Re-Ablation nach Rezidiv?

Europäische Ernährungsgewohnheiten: Das sind die häufigsten Fehler

Hinter dieser Appendizitis steckte ein Erreger

Demenzkranke durch Antipsychotika vielfach gefährdet

Update Innere Medizin

Live-Webinar: Aktuelle Leitlinien bei Herz-Kreislauf-Erkrankungen

Springer Medizin

Abstract

Purpose of Review

Recent Findings

Summary

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 2/2020

Dysfunctional Immunometabolism in HIV Infection: Contributing Factors and Implications for Age-Related Comorbid Diseases

Opportunities and Challenges in HIV Treatment as Prevention Research: Results from the ANRS 12249 Cluster-Randomized Trial and Associated Population Cohort

Obesity and Weight Gain in Persons with HIV

Defining T Cell Tissue Residency in Humans: Implications for HIV Pathogenesis and Vaccine Design

HIV/AIDS Among Female Sex Workers in China: Epidemiology and Recent Prevention Strategies

Assessing and Addressing Social Determinants of HIV among Female Sex Workers in the Dominican Republic and Tanzania through Community Empowerment-Based Responses

Leitlinien kompakt für die Innere Medizin

Neu im Fachgebiet Innere Medizin

Wie erfolgreich ist eine Re-Ablation nach Rezidiv?

Europäische Ernährungsgewohnheiten: Das sind die häufigsten Fehler

Hinter dieser Appendizitis steckte ein Erreger

Demenzkranke durch Antipsychotika vielfach gefährdet

Update Innere Medizin